SciELO - Scientific Electronic Library Online

 
vol.41 número5Quantitative measurement of impairment in ADHD: perspectives for research and clinical practice índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

Compartilhar


Archives of Clinical Psychiatry (São Paulo)

versão impressa ISSN 0101-6083

Resumo

NICIU, MARK J. et al. Biomarkers in mood disorders research: developing new and improved therapeutics. Arch. Clin. Psychiatry [online]. 2014, vol.41, n.5, pp.131-134. ISSN 0101-6083.  https://doi.org/10.1590/0101-60830000000027.

Background

Recently, surrogate neurobiological biomarkers that correlate with target engagement and therapeutic response have been developed and tested in early phase studies of mood disorders.

Objective

The identification of biomarkers could help develop personalized psychiatric treatments that may impact public health.

Methods

These biomarkers, which are associated with clinical response post-treatment, can be directly validated using multimodal approaches including genetic tools, proteomics/metabolomics, peripheral measures, neuroimaging, biostatistical predictors, and clinical predictors.

Results

To date, early phase biomarker studies have sought to identify measures that can serve as “biosignatures”, or biological patterns of clinical response. These studies have also sought to identify clinical predictors and surrogate outcomes associated with pathophysiological domains consistently described in the National Institute of Mental Health’s (NIMH) new Research Domain Criteria (RDoC). Using the N-methyl-D-aspartate (NMDA) antagonist ketamine as an example, we identified changes in several domains (clinical, cognitive, and neurophysiological) that predicted ketamine’s rapid and sustained antidepressant effects in individuals with treatment-resistant major depressive disorder (MDD) or bipolar depression.

Discussion

These approaches may ultimately provide clues into the neurobiology of psychiatric disorders and may have enormous impact Backon the development of novel therapeutics.

Palavras-chave : Biomarker; depression; bipolar disorder; anxiety; drug development.

        · texto em Inglês     · Inglês ( pdf )